In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cephalon publicly sells stock to net $288mm

Executive Summary

Cephalon (cancer, neurology, and inflammatory disease therapeutics) has netted $288mm through the public offering of 5mm common shares at $60 each. The company concurrently sold 2.50% five-year senior subordinated notes (including the overallotment) netting $485mm. The notes convert into cash and shares at $69 each (or 14.49 shares per $1k).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies